GSK to pay Hengrui US$12.5 billion for global rights to 12 drug projects
- Posted on July 28, 2025
- By South China Morning Post
- 2 Views
GSK to pay Hengrui US$12.5 billion for global rights to 12 drug projects
The deal would give GSK the rights to develop the drug for HRD-9821 and 11 preclinical programmes owned by Jiangsu Hengrui Pharmaceuticals.
